Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of epidemiology"
DOI: 10.1093/aje/kwac021
Abstract: Case reports and a pharmacovigilance analysis have linked glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with anaphylactic reactions, but real-world evidence for this possible association is lacking. Using databases from the United Kingdom (Clinical Practice Research… read more here.
Keywords: reaction; glp ras; risk anaphylactic; glucagon like ... See more keywords